Relay Therapeutics, Inc. (RLAY) Presents at TD Cowen 46th Annual Health Care Conference Transcript [Seeking Alpha]
Relay Therapeutics, Inc. (RLAY)
Company Research
Source: Seeking Alpha
Sanjiv Patel - CEO, President & Director Peter Rahmer - Chief Corporate Development Officer Donald Bergstrom - President of Research & Development Conference Call Participants Yaron Werber - TD Cowen, Research Division Jaena Han - TD Cowen, Research Division Presentation Yaron Werber TD Cowen, Research Division Welcome once again to the 46th Annual TD Cowen Healthcare Conference. I'm Yaron Werber from the TD Cowen Biotech team. It's a great pleasure to moderate the next fireside chat with Relay Therapeutics. With us today, we have Sanjiv Patel, President and CEO; to his left, we've got Peter Rahmer, Chief Corporate Development Officer; to his left, Don Bergstrom, President of R&D; and with us today, Jaena Han as well from our team. So I think we have a few slides to go through, and then we'll actually start the presentation thereafter in Q&A on vascular malformations, which is a new and important new area, and then we'll talk about breast cancer. Sanjiv Patel CE
Show less
Read more
Impact Snapshot
Event Time:
RLAY
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
RLAY alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
RLAY alerts
High impacting Relay Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
RLAY
News
- Is Relay Therapeutics a Buy in 2026? One Institutional Investor Just Made a $6 Million Bet. [Yahoo! Finance]Yahoo! Finance
- Relay Therapeutics (RLAY) had its price target raised by Citizens Jmp from $15.00 to $17.00. They now have a "market outperform" rating on the stock.MarketBeat
- Relay Therapeutics (RLAY) had its price target raised by Wells Fargo & Company from $15.00 to $17.00. They now have an "overweight" rating on the stock.MarketBeat
- Relay Therapeutics (RLAY) had its "outperform" rating reaffirmed by Oppenheimer Holdings, Inc..MarketBeat
- Relay Therapeutics Announces Data from Zovegalisib + Fulvestrant at the Phase 3 Dose of 400mg BID Fed at ESMO Targeted Anticancer Therapies Congress 2026GlobeNewswire
RLAY
Earnings
- 2/26/26 - Beat
RLAY
Sec Filings
- 3/19/26 - Form SCHEDULE
- 3/16/26 - Form 8-K
- 3/11/26 - Form 4
- RLAY's page on the SEC website